The role of integrin antagonists in the treatment of inflammatory bowel disease

Bibliography

• Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995;30:699-706
   PubMed Web of Science ®Google Scholar
• Faubion WAJr, Loftus EVJr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2002;121:255-60
   Web of Science ®Google Scholar
• Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24:319
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn′s disease. Gut 1994;35:360-2
   PubMed Web of Science ®Google Scholar
• Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clinical North Am 2010;24:285-306
   PubMed Web of Science ®Google Scholar
• Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46
   PubMed Web of Science ®Google Scholar
• Targownik L, Bernstein C. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013;108:1835-42
   PubMed Web of Science ®Google Scholar
• Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. ClinExpRheumatol 2002;20(Suppl 28):S152-7
   Google Scholar
• Ben-Horin S, Kopylov U, Choweres Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014;13:24-30
   PubMed Web of Science ®Google Scholar
• Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of Crohn’s disease. TherAdv Gastroenterol 2009;2:244-51
   Google Scholar
• Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Disease 2005;37:811-18
   Web of Science ®Google Scholar
• Springer T. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14
   PubMed Web of Science ®Google Scholar
• Ghosh N, Chaki R, Mandal SC. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease. Int Reviews of Immunol 2012;31:410-27
   PubMed Web of Science ®Google Scholar
• Druan I, Martinez-Caceres EM, Rio J, et al. Immunological profile of patients with primary progressive multiple sclerosis: expression of adhesion molecules. Brain 1999;122:2297-307
   PubMed Web of Science ®Google Scholar
• Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005;4:510-18
   PubMed Web of Science ®Google Scholar
• Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. CurrMol Med 2009;9:836-50
   PubMed Web of Science ®Google Scholar
• Hemler ME, Huang C, Takada Y, et al. ‘Characterization of the cell surface heterodimer VLA-4 and related peptides’. J Biol Chem 1987;262(24):11478-85
   Google Scholar
• Jackson DY. ‘Alpha 4 integrin antagonists’. Curr Pharm Des 2002;8(14):1229-53
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. New Engl J Med 2003;348:24-32
   PubMed Web of Science ®Google Scholar
• Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352:1742-6
   PubMed Web of Science ®Google Scholar
• Farstad IN, Halstensen TS, Kvale D, et al. Topographic distribution of homing receptors on B and T cells in human gut-associated lymphoid tissue. Am J Pathology 1997;150:187-99
   PubMed Web of Science ®Google Scholar
• Meenan J, Spaans J, Grool TA, et al. ‘Altered expression of alpha-4 beta-7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation’. Gut 1997;40:241-6
   PubMed Web of Science ®Google Scholar
• Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha4 integrin monoclonal antibody. J Clin Invest 1993;92(1):378-80
   Google Scholar
• Park EJ, Mora JR, Carman CV, et al. Aberrant activation of integrin alpha-4beta-7 suppresses lymphocyte migration to the gut. J Clinical Invest 2007;117(9):2526-38
   PubMed Web of Science ®Google Scholar
• Leger OJP, Yednock TA, Tanner L, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997;8:3-16
   PubMedGoogle Scholar
• Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70(3):439-44
   PubMed Web of Science ®Google Scholar
• Gordon FH, Lai CWY, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha-4 integrin in active Crohn’s disease. Gastroenterology 2001;121:268-74
   PubMed Web of Science ®Google Scholar
• Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27:533-7
   PubMed Web of Science ®Google Scholar
• Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699-705
   PubMed Web of Science ®Google Scholar
• Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96(3):804-10
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enn R. Natalizumab induction and maintenance therapy for Crohn’s disease. New Engl J Med 2005;353:1912-25
   PubMed Web of Science ®Google Scholar
• Ware Jr J E, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30(6):473-83
   PubMed Web of Science ®Google Scholar
• Rabin R, deCharro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Hass S, et al. Health-related quality of life during natalizumab maintenance therapy for Crohn’s disease. Am J Gastroenterol 2007;102(12):2737-46
   PubMed Web of Science ®Google Scholar
• Sands BE, Kozark R, Spain hour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with crohn’s disease not in remission while receiving infliximab. Inflam Bowel Dis 2007;13(1):2-11
   PubMed Web of Science ®Google Scholar
• Calabrese L.H, Molloy ES, Huang D, et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56:2116-28
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 1996;70(10):7004-12
   PubMed Web of Science ®Google Scholar
• Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infectious Dis 2009;199(6):837-46
   PubMed Web of Science ®Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9(4):425-37
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopath. New Engl J Med 2006;354(9):924-33
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-9
   PubMed Web of Science ®Google Scholar
• Gorelick L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303
   PubMed Web of Science ®Google Scholar
• Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the Mad-CAM-1 receptor, integrin alpha-4,beta-7 on human leukocytes. J Immunol 1994;153:517-28
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to gut-homing integrin alpha-4,beta-7. Gastroenterology 1996;111:1373-80
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha-4,beta-7 integrin. New Engl J Med 2005;352(24):2499-507
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha-4,beta-7 integrin’. Clin Gastroenterol Hepatol 2008;6:1370-77
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2003;348:15-23
   PubMed Web of Science ®Google Scholar
• Feagan BJ, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New Eng Journal Med 2013;369(8):699-710
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BJ, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. New Engl J Med 2013;369(8):711-21
   PubMed Web of Science ®Google Scholar
• Oshitani N, Watanabe K, Maeda K. Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD 103 with epithelial adhesion molecules in inflammatory bowel disease. Int J Mol Medicine 2003;12:715-19
   PubMed Web of Science ®Google Scholar
• Stefanich EJ, Danilenko DM, Wang H, et al. A humanized monoclonal antibody targeting the beta-7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011;162:1855-70
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Williams M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomized, controlled, phase 2 trial. The Lancet 2014;384:309-18
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Khanna N, Tan CS, et al. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011;53:711-15
   PubMed Web of Science ®Google Scholar
• Ropper AH. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab. N Engl J Med 2012;366(20):1938-9
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. New Engl J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400
   PubMed Web of Science ®Google Scholar